Biomarker Driven Patient Selection Neoadjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
Conditions: Melanoma Stage III; Melanoma Stage IV; Advanced Melanoma; Melanoma Interventions: Drug: Nivolumab; Drug: Nivolumab + Relatlimab; Drug: Ipilimumab Sponsors: H. Lee Moffitt Cancer Center and Research Institute Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Melanoma | Neoadjuvant Therapy | Research | Skin Cancer | Yervoy